Clinical Trial Update: An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 [Phase 2]

View source ↗

Summary

Extension phase 2 study update for YM-155 in prostate cancer, melanoma, and non-Hodgkin lymphoma; status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-hodgkin Lymphoma
• Prostate Cancer

Drugs mentioned

• YM-155

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Prostate Cancer, Melanoma | Phase 2 | Status: COMPLETED